Fast Five Quiz: Early Non–Small Cell Lung Cancer

Daniel S. Schwartz, MD


May 24, 2022

Surgical resection by anatomic lobectomy with mediastinal lymph node analysis confers the best chance for cure among medically fit patients with early-stage NSCLC. Therefore, it is considered the treatment of choice in this setting, per NCCN guidelines.

Patients who are not prime candidates for surgery owing to either underlying medical conditions or borderline pulmonary function may better tolerate a minimally invasive approach to surgery with a sub-lobar resection.

Evidence suggests that cisplatin-based therapy may be the most effective single drug for treating NSCLC patients used for treating advanced cancers. While vinorelbine/cisplatin is sometimes considered the preferred regimen for completely resected early-stage NSCLC, most clinicians opt for a less toxic regimen.

Learn more about treatment of NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.